A. Spickard, M.D.; W. Butler, M.D.; J. P. Utz, M.D. (Assoc.)
This content is PDF only. Please click on the PDF icon to access.
The discovery of amphotericin-B and its antifungal effect in cryptococcal meningitis in man has drastically changed the prognosis of this heretofore universally fatal disease. By analysis of 34 cases studied during the past seven years at the Clinical Center, this report attempts to define the beneficial effect of the drug and some of the factors that may influence response to treatment.
Of the 34 cases studied, five received no amphotericin-B, and all died. Twenty-nine patients were treated with follow-up observation periods ranging from six months to over five years. Of these 29 cases, 22 had improvement subjectively and in their
Spickard A, Butler W, Utz JP. The Improved Prognosis of Cryptococcal Meningitis with Amphotericin-B Therapy.. Ann Intern Med. ;56:691. doi: 10.7326/0003-4819-56-4-691_1
Download citation file:
Published: Ann Intern Med. 1962;56(4):691.
CNS Infections, Infectious Disease, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use